Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3Phase 3 1Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 7Lymphoid 3Head & Neck 3Thoracic 2Genitourinary 2Dermatologic 2Breast 2Tumor-Agnostic 1Sarcoma 1Other hematologic neoplasm 1Gynecologic 1

Conditions

Lymphoma, B-Cell, Marginal Zone 2Lymphoma, Non-Hodgkin 1

Interventions

Rituximab 689Cyclophosphamide 615Vincristine 285Etoposide 272Doxorubicin 271Cytarabine 230Prednisone 229Methotrexate 221fludarabine phosphate 189Filgrastim 187Dexamethasone 180fludarabine 176Lenalidomide 165Radiotherapy 128Melphalan 127Peripheral Blood Stem Cell Transplantation 123Busulfan 118Bendamustine Hydrochloride 116Granulocyte Colony-Stimulating Factor 113Bortezomib 112ibrutinib 111Mycophenolic Acid 110venetoclax 106Whole-Body Irradiation 106obinutuzumab 105Tacrolimus 105Gemcitabine 92zanubrutinib 81Specimen Handling 80Cyclosporine 76

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Pharmaceutical Preparations × Lymphoid × Clear all
NCT00596154 2024-04-01

PCNSL

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
33 enrolled 9 charts
Lymphoid

Lymphoma, Non-Hodgkin

NCT00210392 2015-03-30

VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy

International Extranodal Lymphoma Study Group (IELSG)

Phase 2 Terminated
12 enrolled
Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT00210327 2009-07-22

VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy

International Extranodal Lymphoma Study Group (IELSG)

Phase 2 Completed
33 enrolled
Lymphoid

Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡